What’s the current market cap for Chemed stock?

Chemed (CHE) has a market cap of $5.6B as of June 02, 2026.

What is the P/E ratio for Chemed stock?

The price to earnings (P/E) ratio for Chemed (CHE) stock is 23.11 as of June 02, 2026.

Does Chemed stock pay dividends?

Yes, the Chemed (CHE) stock pays dividends to shareholders. As of June 02, 2026, the dividend rate is $2.3 and the yield is 0.57%. Chemed has a payout ratio of 12.53% on a trailing twelve-month basis.

When is the next Chemed dividend payment date?

The next Chemed (CHE) dividend payment is scheduled for June 16, 2026.

What is the beta indicator for Chemed?

Chemed (CHE) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Chemed stock | $CHE Share Price

13:30

09:10

04:45

00:25

20:00

About Chemed

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Ticker

$CHE

Sector

Health

Primary listing

NYSE

Employees

15,811

Headquarters

Cincinnati, United States

Website

www.chemed.com

Chemed Metrics

BasicAdvanced

$5.6bn

23.11

$18.30

0.54

$2.30

0.57%

What the Analysts think about Chemed

Analyst ratings (Buy, Hold, Sell) for Chemed stock.

Bulls say / Bears say

VITAS hospice segment net patient revenue rose 3.1% to $420.0 million in Q1 2026, with average daily census up 2.2% and admissions climbing 6.9%, demonstrating robust demand for end-of-life care. (Chemed Q1 2026 Results)

Chemed raised full-year 2026 guidance, increasing expected ADC growth to 4.5%–5.5%, revenue growth (excluding Medicare Cap) to 6.5%–7.5%, and adjusted EPS to $24.00–$24.75, reflecting strong operational momentum at VITAS. (Chemed Q1 2026 Results)

Chemed repurchased 500,000 shares for $197.7 million in Q1 and retains $229.6 million of repurchase authorization, demonstrating commitment to capital return and EPS accretion. (Chemed Q1 2026 Results)

Roto-Rooter segment revenue declined 0.9% year-over-year in Q1 2026, with adjusted EBITDA down 9.6% and margins contracting by 218 basis points, underscoring persistent profitability pressures in the plumbing business. (Chemed Q1 2026 Results)

Chemed lowered its full-year Roto-Rooter EBITDA margin guidance to 21.5%–22.5% (from 22.5%–23.0%) due to elevated marketing expenses and weather-related service disruptions, signaling continued headwinds. (Chemed Q1 2026 Results)

Consolidated revenue growth was a modest 1.6% in Q1 and GAAP diluted EPS fell 0.4% to $4.84, highlighting limited top-line expansion and underlying earnings pressures. (Chemed Q1 2026 Results)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

Chemed Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Chemed Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CHE

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Consolidated revenue growth was a modest 1.6% in Q1 and GAAP diluted EPS fell 0.4% to $4.84, highlighting limited top-line expansion and underlying earnings pressures. (Chemed Q1 2026 Results)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About Chemed

Ticker

Primary listing

Employees

Chemed Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Chemed

Analyst Ratings

Bulls say / Bears say

Chemed Financial Performance

Income Statement

Chemed Earnings Performance

Earnings per share (EPS)

Buy $CHE

Upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Chemed/$CHE

About Chemed

Ticker

Primary listing

Employees

Chemed Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Chemed

Analyst Ratings

Bulls say / Bears say

Chemed Financial Performance

Income Statement

Chemed Earnings Performance

Earnings per share (EPS)

Buy $CHE

Upcoming events

What’s the current market cap for Chemed stock?

What is the P/E ratio for Chemed stock?

Does Chemed stock pay dividends?

When is the next Chemed dividend payment date?

What is the beta indicator for Chemed?

Bulls say / Bears say